Every 8-K that Syndax Pharmaceuticals, Inc. (SNDX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SNDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNDX filings page.
Syndax Pharmaceuticals reported strong second‑quarter 2026 results, with total revenue of $72.8 million, up 92% year over year, driven by Revuforj net revenue of $54.7 million and Niktimvo collaboration revenue of $18.1 million. Niktimvo’s underlying net revenue was $60.3 million. Operating expenses were $112.8 million, leading to a net loss of $49.4 million, or $0.55 per share, an improvement from a $71.8 million loss a year earlier. Cash, cash equivalents, and investments totaled $575.1 million as of June 30, 2026, with 89.4 million common shares and prefunded warrants outstanding.
The company highlighted rapid commercial uptake, including approximately 1,500 Revuforj prescriptions in the quarter and six consecutive quarters of double‑digit revenue and prescription growth. Multiple Phase 2 and Phase 3 trials are underway across acute leukemia, chronic graft‑versus‑host disease, idiopathic pulmonary fibrosis, myelofibrosis, and EGFR‑mutated non‑small cell lung cancer, alongside new assets SNDX‑4321 and SNDX‑62122. For full‑year 2026, Syndax continues to expect combined R&D and SG&A expenses of about $400 million, excluding $50 million of estimated non‑cash stock compensation, and states that its liquidity and anticipated revenues are expected to enable it to reach profitability.
Syndax Pharmaceuticals describes itself as a commercial‑stage biopharmaceutical company with two FDA‑approved medicines: Revuforj (revumenib), a menin inhibitor, and Niktimvo (axatilimab‑csfr), a CSF‑1R‑blocking antibody for chronic GVHD. Both drugs were annualizing at ~$200M as of 1Q26. The company cites a solid financial position, growing revenues and a path toward profitability, and says it is fully funded to advance late‑stage trials and pipeline assets.
The company outlines a deep pipeline. New assets include SNDX‑4321, a mutant‑selective allosteric EGFR inhibitor for EGFR‑mutated NSCLC, with an IND submission planned by year‑end 2026 and a Phase 1 trial in 2027, and SNDX‑62122, a next‑generation menin inhibitor for myelofibrosis, with IND filing and Phase 1 initiation also expected in 2027.
Ongoing programs feature late‑stage revumenib trials across multiple acute leukemia settings, axatilimab in chronic GVHD, and the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis, for which topline data are expected in 4Q26. A revumenib proof‑of‑principle trial in myelofibrosis is anticipated to start in 4Q26 with initial data in the second half of 2027, contributing to at least four clinical assets expected in 2027.
Syndax Pharmaceuticals, Inc. issued $250.0 million of 2.25% Convertible Senior Notes due 2031 in a private placement to institutional investors. The notes were issued under an indenture with U.S. Bank Trust Company, National Association, as trustee.
Net proceeds were approximately $243.0 million after fees and expenses, which Syndax expects to use for general corporate purposes, including working capital, research and development, commercialization activities and business development. The notes and any conversion shares were sold relying on registration exemptions under Sections 4(a)(2) and 3(a)(9) of the Securities Act.
Based on an initial maximum conversion rate of 54.5256 shares per $1,000 principal amount, up to 13,631,400 shares of common stock may initially be issuable upon conversion, subject to customary anti-dilution adjustments.
Syndax Pharmaceuticals, Inc. reported results from its June 10, 2026 annual stockholder meeting, where all proposals passed. Stockholders approved the 2026 Equity Incentive Plan, which reserves 7,200,000 shares of common stock plus shares that may return from expired or forfeited awards under the prior 2015 plan.
They also approved a new 2026 Employee Stock Purchase Plan to replace the 2015 plan, with U.S. and non-U.S. components, both effective June 10, 2026. Stockholders elected all nominated directors, gave advisory approval to executive compensation, and ratified the company’s independent public accounting firm.
Syndax Pharmaceuticals has entered into privately negotiated subscription agreements to issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a private placement, with expected net proceeds of about $243 million.
The notes are senior unsecured, pay 2.25% interest semiannually starting December 15, 2026, and mature on June 15, 2031, unless earlier converted, redeemed or repurchased. They are initially convertible at 40.3894 shares of common stock per $1,000 principal (an effective conversion price of about $24.76 per share), representing a roughly 35% premium to the June 3, 2026 share price. Under a higher maximum conversion rate of 54.5256 shares per $1,000, up to 13,631,400 shares may be issued.
Syndax may redeem the notes for cash on or after June 20, 2029 if its stock trades at least 130% of the conversion price for a specified period. Noteholders have conversion and repurchase rights upon certain trading, corporate or “fundamental change” events. The company plans to use proceeds for general corporate purposes, including working capital, research and development, commercialization and business development.
Syndax Pharmaceuticals reported first quarter 2026 revenue of $64.9 million, a 224% year-over-year increase driven by strong launches of Revuforj and Niktimvo. Revuforj net revenue reached $48.9 million, reflecting rapid uptake in relapsed or refractory NPM1-mutated and KMT2A-rearranged acute leukemias and growing use around stem cell transplant.
Niktimvo generated $55.1 million in net revenue at partner Incyte, producing $15.9 million of collaboration revenue for Syndax. Operating expenses declined modestly, and the net loss narrowed to $42.7 million, or $0.48 per share, compared with $84.8 million a year earlier.
The company ended the quarter with $352.1 million in cash, cash equivalents and short-term investments and 88.8 million common shares and prefunded warrants outstanding. Syndax guides to about $400 million in 2026 R&D plus SG&A (excluding $50 million non-cash stock compensation) and expects its current cash, investments, product and collaboration revenue, and interest income to support a path to profitability.
Syndax Pharmaceuticals reported strong commercial growth for 2025 as it ramped launches of Revuforj and Niktimvo. Total revenue reached $68.7 million in the fourth quarter and $172.4 million for 2025, driven by Revuforj net revenue of $124.8 million and Niktimvo collaboration revenue of $42.4 million.
The company remains loss-making, with a 2025 net loss attributable to common stockholders of $285.4 million, or $3.29 per share, but narrowed its loss versus 2024. Cash, cash equivalents and short-term investments were $394.1 million as of December 31, 2025, supporting an R&D and SG&A expense outlook of about $400 million for 2026.
Management highlighted accelerating prescription trends, multiple late-stage trials for Revuforj across acute leukemia settings, and completion of enrollment in the Phase 2 IPF trial of axatilimab, with topline data expected in the fourth quarter of 2026 as it targets a path to profitability.
Syndax Pharmaceuticals reported preliminary unaudited 2025 figures alongside a presentation at the 44th Annual J.P. Morgan Healthcare Conference. The company estimates U.S. net product revenue for Revuforj® (revumenib) at approximately $44 million for the fourth quarter and $125 million for the full year ended December 31, 2025. Niktimvo™ (axatilimab-csfr) generated an estimated $56 million in U.S. net product revenue for the quarter and $152 million for the full year, with Syndax to report its share of net commercial profit when it releases full-year 2025 results. The company also disclosed preliminary total cash, cash equivalents and marketable securities of about $394 million as of December 31, 2025. All figures are unaudited and subject to change as the year-end audit is completed.
Syndax Pharmaceuticals, Inc. filed a current report announcing that it released its financial results for the quarter and six months ended September 30, 2025. On November 3, 2025, the company issued a press release and a corporate presentation describing these results, which are included as Exhibits 99.1 and 99.2. The company notes that this earnings information is being furnished rather than filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other SEC filings unless specifically referenced.
Syndax Pharmaceuticals (SNDX) announced FDA approval of Revuforj (revumenib) for the treatment of relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options. The company disclosed the news via a press release and held a conference call on October 24, 2025.
The filing notes forward-looking statements regarding plans to make Revuforj commercially available for this indication. A copy of the press release is furnished as Exhibit 99.1.
Syndax Pharmaceuticals (Nasdaq:SNDX) filed an 8-K under Item 5.02 reporting the resignation of director William Meury, effective June 24 2025. Meury stepped down to become President, CEO and board member of Incyte Corporation, Syndax’s collaboration partner on Niktimvo™ (axatilimab-csfr). The company states the departure involves no disagreements regarding its operations, policies or practices. No successor or board-composition changes were disclosed.
While day-to-day operations and partnership terms remain unchanged, investors should watch for follow-up filings detailing any replacement director or shifts in oversight of the Incyte collaboration.